MNKD
Mannkind Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
Market Cap: 1.3 Billion
Primary Exchange: NASDAQ
Website: http://www.mannkindcorp.com/
Shares Outstanding: 270 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.3393281678478448
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2977 trading days
From: 2014-06-30 To: 2024-03-07
Lowest Point:
MNKD, DATA among premarket gainers
via: SeekingAlpha at 2019-06-10 05:13:59:000
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more … read more...
MNKD, DATA among premarket gainers
via: SeekingAlpha at 2019-06-10 05:13:59:000
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more … read more...
MNKD, DATA among premarket gainers
via: SeekingAlpha at 2019-06-10 05:13:59:000
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more … read more...
MNKD, DATA among premarket gainers
via: SeekingAlpha at 2019-06-10 05:13:59:000
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more … read more...
MannKind up 14% premarket on new Afrezza data
via: SeekingAlpha at 2019-06-10 03:32:05:000
MannKind (NASDAQ: MNKD ) is up 14% premarket on modest volume on the heels of data from three studies of inhalable Afrezza (insulin human). The data were presented at the American Diabetes Association Scientific Sessions inSan Francisco. More news on: MannKind Cor… read more...
MannKind up 14% premarket on new Afrezza data
via: SeekingAlpha at 2019-06-10 03:32:05:000
MannKind (NASDAQ: MNKD ) is up 14% premarket on modest volume on the heels of data from three studies of inhalable Afrezza (insulin human). The data were presented at the American Diabetes Association Scientific Sessions inSan Francisco. More news on: MannKind Cor… read more...
MannKind up 14% premarket on new Afrezza data
via: SeekingAlpha at 2019-06-10 03:32:05:000
MannKind (NASDAQ: MNKD ) is up 14% premarket on modest volume on the heels of data from three studies of inhalable Afrezza (insulin human). The data were presented at the American Diabetes Association Scientific Sessions inSan Francisco. More news on: MannKind Cor… read more...
MannKind up 14% premarket on new Afrezza data
via: SeekingAlpha at 2019-06-10 03:32:05:000
MannKind (NASDAQ: MNKD ) is up 14% premarket on modest volume on the heels of data from three studies of inhalable Afrezza (insulin human). The data were presented at the American Diabetes Association Scientific Sessions inSan Francisco. More news on: MannKind Cor… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2017-03-03 | 5.0 | 1.0 | 5.0 |